Bipolar disorder; manic-depressive illness (MDI); bipolar depression; mania DEFINITION Bipolar affective disorder is one of the most common, severe and persistent mental illnesses. Bipolar disorder is characterized by periods of deep, prolonged and profound depression, alternating with periods of excessively elevated and/or irritable mood (mania).
CHARACTERISTICS

History/Background
Bipolar affective disorder or manic depressive illness has been recognized since at least the time of Hippocrates who described such persons as "amic" and "melancholic". In 1899 the German psychiatrist Emil Kraepelin defined manic-depressive illness and noted that sufferers lacked deterioration and dementia, normally associated with schizophrenia.
Both modern classification systems (ICD and DSM) contain categories for both single episodes and recurrent episodes of mood disorder, and repeatedly alternating high and low mood is described as cyclothymia. Hypomania is distinguished from mania because of the difference in the degree of severity of symptoms and social incapacity.
Diagnostic considerations
Bipolar affective disorder is a recurrent and disabling mental illness, typically beginning early in life. It constitutes one pole of a spectrum of mood disorders including bipolar I (BP I), bipolar II (BP II), cyclothymia (oscillating high and low mood) and major depression [1] . BP I is also referred to as classic manic depression and is characterized by distinct episodes of major depression contrasting vividly with episodes of mania which lead to a severe impairment in function. In comparison, BP II is a milder disorder consisting of depression alternating with periods of hypomania [2] .
Although bipolar affective disorder is defined by manic and hypomanic episodes, in most cases the depressive episodes constitute the more virulent aspect of the illness. The depressive episodes are usually more frequent, of longer duration, and are more difficult to treat than the manic episodes. Moreover, depression is the principle cause of the illness's high suicide rate [3, 4] .
Epidemiology
Findings from recent studies generally report an overall lifetime prevalence of bipolar I disorder of around 1 to 1.5%. This percentage range hardly varies from country to country. In the United States, Europe, Scandinavia, the South Pacific, South America and the United Kingdom the lifetime prevalence of bipolar I disorder ranges from 0.2% (Iceland) to 2.0% (The Netherlands and Hungary). Exceptionally low prevalence rates can be found in Iceland (0.2%) and three Asian countries (0.015 -0.3%). The reasons for the particularly low rates in Asian countries are unclear (e.g. genetic, cultural or diagnostic factors) [5] .
The two types of disorder differ in adult populations, BP I occurring in approximately 0.8% and BP II in approximately 0.5%. Studies involving a broad bipolar spectrum produce much higher lifetime prevalence rates of 3.0 to 8.3%. The validity of such studies, however, may be questionable in view of the fact that it is difficult to distinguish between normal mood and mild hypomania.
Most studies have not shown large differences in bipolar disorder rates with regard to gender. The illness is more prevalent in divorced or separated than in married persons. Differences concerning social class and ethnic group are less well documented. Pregnancy and the menopause represent periods of greater vulnerability for the development of manic episodes in females. A family history of bipolar disorder in a first-degree relative remains the strongest predictor.
The WHO has ranked bipolar disorder among the top 10 disabling disorders in both developed and developing countries.
Course and outcome
The age of onset of bipolar disorders varies greatly. It ranges for both BP I and BP II from childhood to 50 years, with a mean age of approximately 21 years. Most cases commence at the age of 15 -19 years, the second most frequent age range is 20 -24 years. Some patients diagnosed with recurrent major depression may indeed have bipolar disorder and develop their first manic episode after the age of 50 [6] . They may have a family history of bipolar disorder. However, if manic episodes develop after the age of 50, it is advisable to examine the patient for medical or neurological disorders such as cerebro-vascular disease. Almost all bipolar patients experience relapse, given adequate observation time. Cycle length does not change predictably over time, although it may shorten progressively in the initial stages of the illness in a sub-group of individuals. A significant proportion of bipolar patients develop rapid cycling [7] . Manic episodes are briefer than depressive or mixed episodes. The average episode duration remains stable throughout the illness. About 1 to 2% of unipolar depressive patients per year experience a first manic or hypomanic episode, suggesting that over a long follow-up period a significant minority of patients previously diagnosed with unipolar depression will subsequently have their diagnosis changed to bipolar disorder. Initial episodes of depression are commonly misdiagnosed and this not only often delays starting appropriate therapy but also increases the likelihood of the illness being treated with antidepressants alone. Unfortunately, the correct diagnosis is often only arrived at after a treatment-emergent affective switch has occurred [4] .
Psychosocial and physical stress situations still appear to be strong predictors for relapse, although such severe life events most likely interact with the patients' underlying vulnerability in a complex manner. Life events appear to be more strongly associated with relapse in earlier than in later phases of bipolar illness.
Long-term data suggest that up to one third of bipolar patients achieve complete remission, and a similar number achieve complete functional recovery. Although syndromal recovery is at least twice as frequent, fewer patients ultimately recover pre-morbid levels of functioning. Chronic persistence of symptoms can be expected in about 20% of cases, and social incapacity in about 30% [5] .
Early age of onset, depression, mixed episodes, psychosis, substance abuse, medication noncompliance and probably the long-term use of antidepressants are all associated with poor outcome. Mortality and suicide rates are higher in bipolar illness, but can be substantially reduced by adequate lithium treatment.
Pathophysiology
Up to now, no objective biological markers have been found that correspond definitively with the illness state. However, twin, family and adoption studies all indicate strongly that bipolar disorder has a genetic component. In fact, first-degree relatives of bipolar patients are approximately seven times more likely to develop the disorder than the rest of the population.
Findings from gene expression studies of post-mortem brain tissue from bipolar disorder patients have stressed that levels of expression of oligodendrocyte-myelin-related genes appear to be decreased in brain tissue from bipolar disorder patients [8] . Oligodendrocytes produce myelin membranes that wrap themselves around axons, insulating them and permitting the efficient conduction of nerve impulses in the brain. Therefore, loss of myelin is thought to disrupt communication between neurons, leading to some of the thought disturbances observed in bipolar disorder and related illnesses.
Brain imaging studies in patients with bipolar disorder also show abnormal myelination in several brain regions associated with the illness [9] . Interestingly, gene expression and neuroimaging studies in persons with schizophrenia and major depression also demonstrate similar findings, indicating that mood disorders and schizophrenia may share some biological underpinning.
Another approach to investigating the pathophysiology of bipolar disorder involves studying changes in gene expression induced in rodent brains after administration of pharmacological agents used to treat bipolar disorder. For example, two chemically unrelated drugs used to treat bipolar disorder, lithium and valproate, both up-regulate the expression of the cytoprotective protein Bcl-2 in the frontal cortex and the hippocampus of rat brains. Neuroimaging studies of individuals with bipolar disorder or other mood disorders also suggest evidence of cell loss or atrophy in these same brain regions. Thus, another suggested cause of bipolar disorder is damage to cells in the critical brain circuit that regulates emotion. According to this hypothesis, mood stabilizers and antidepressants are thought to alter mood by stimulating cell survival pathways and increasing levels of neurotrophic factors to improve cellular resiliency.
Post and Weiss [10] proposed a mechanism involving electrophysiological kindling and behavioural sensitization processes, a method also seen in previous hypotheses based on neuronal injury. Post asserts that an individual susceptible to bipolar disorder experiences an increasing number of minor neurological assaults, perhaps caused by drug-abuse, and excessive glucocorticoid stimulation, resulting from acute or chronic stress or other factors, which eventually results in mania. Subsequently, sufficient brain damage might persist causing mania to recur even with no or only minor environmental or behavioural stress (see Fig. 1 ). This type of formulation helps explain the effective role of anticonvulsant medications, e.g. carbamazapine and valproate, in the prevention of highs or lows in bipolar disorder. It also suggests that the more episodes a person experiences, the more he or she will have in the future, underlining the need for long-term treatment. 
Psychopharmacotherapy
There are no specifically approved treatments for bipolar disorder in youth and, among antidepressants, only the selective serotonin-reuptake inhibitor fluoxetine has received approval.
When bipolarity is suspected, treatment with mood stabilizers, both conventional (lithium [11] and the anticonvulsant medications, valproate and carbamazapine) and those more recently classified (lamotrigine), and atypical antipsychotics should be prioritised. When antidepressants are indicated in combination with mood stabilizers, first-choice options include bupropion and the selective serotonin-reuptake inhibitors.
The manic patient presents multiple clinical challenges beyond the choice of medication, such as dealing with law enforcement and deciding when to hospitalise the patient against his/her will, how best to involve the family and how to enhance adherence to the treatment regimen. For those patients whose manic episodes are heralded by a hypomanic period, the clinician may have the opportunity to prevent escalation by prescribing drugs to restore normal sleep. An on-going relationship with the family and the patient is the best way of assuring that the clinical is alerted in time.
Psychotherapy and psychosocial interventions
While in most cases drug treatment is effective in eliminating the severe disruptions of manic and depressive episodes, the best treatment results for bipolar affective illness are achieved by combining mood stabilizers or other medications with psychotherapy. Psychotherapy can help the patient come to terms with the repercussions of past episodes and to comprehend the practical and existential implications of the illness.
Educating patients and their families is essential as it helps them recognise the symptoms of emerging episodes. The charting of moods appears to be useful to provide an objective record of mood patterns and treatment response and to give the patient a sense of control and collaboration.
Various forms of psychosocial intervention have been found effective as adjunctive treatments for bipolar disorder. These include family-focussed therapy, interpersonal and social rhythm therapy, cognitive-behavioural therapy and individual or group psychoeducation. When used in conjunction with pharmacotherapy, these interventions may prolong the time up to relapse, reduce symptom severity and increase medication adherence.
Family-focussed therapy aims at reducing the high levels of stress and conflict in the families of bipolar patients, thereby improving the course of the illness. Interpersonal and social rhythm therapy focuses on stabilizing the patient's day and night routines and resolving key interpersonal problems. Cognitive-behavioural therapy helps patients to modify dysfunctional cognition and behaviour that may aggravate the course of the disorder. Group psychoeducation provides a supportive, interactive setting in which patients learn about their illness and how to cope with it. Participation in a self-help group can also supplement, or in some cases, replace formal psychotherapy.
